After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who have at least one underlying condition that puts them at higher risk of severe illness.

Novavax CEO John Jacobs said in a statement that the approval was a "significant milestone" that solidifies a path for people to access the vaccine. The company missed out on the pandemic vaccine windfall due to manufacturing issues and regulatory hurdles.

RFK Jr’s FDA limits use of Covid vaccine - Vaccine expert says health secretary wants to ‘make vaccines less available, more expensive, and more feared’